Journal
BLOOD
Volume 117, Issue 18, Pages 4988-4998Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-11-321190
Keywords
-
Categories
Funding
- National Heart, Lung, and Blood Institute (Public Health Service) [R01-HL55338]
- Johns Hopkins Institute for Cell Engineering
Ask authors/readers for more resources
A major obstacle to using bone marrow cell-based therapies for ischemic cardiovascular disease is that transplanted cells must survive in an ischemic microenvironment characterized by low oxygen, glucose, and pH. We demonstrate that treatment of bone marrow-derived angiogenic cells (BMDACs) with dimethyloxalylglycine, an alpha-ketoglutarate antagonist that induces hypoxia-inducible factor 1 (HIF-1) activity, results in metabolic reprogramming of these cells, with increased glucose uptake, decreased O(2) consumption, increased lactate production, decreased reactive oxygen species, and increased intracellular pH. These effects are dependent on HIF-1, which transactivates target genes encoding metabolic enzymes and membrane transporters. Dimethyloxalylglycine-treated BMDACs have a signifi-cant survival advantage under conditions of low O(2) and low pH ex vivo and in ischemic tissue. Combined HIF-1 alpha-based gene and cell therapy reduced tissue necrosis even when BMDAC donors and ischemic recipient mice were 17 months old, suggesting that this approach may have therapeutic utility in elderly patients with critical limb ischemia. (Blood. 2011; 117(18):4988-4998)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available